Research Article

The Association between VDR Gene Polymorphisms and Diabetic Retinopathy Susceptibility: A Systematic Review and Meta-Analysis

Yun Zhang, Wei Xia, Ping Lu, and Huijuan Yuan

Department of Endocrinology, Henan Provincial People’s Hospital and Zhengzhou University People’s Hospital, Zhengzhou, Henan, China

Correspondence should be addressed to Huijuan Yuan; lmls3712@163.com

Received 14 May 2016; Revised 7 August 2016; Accepted 1 September 2016

Academic Editor: Timothy Y. Lai

Copyright © 2016 Yun Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Aims. Studies on the associations of vitamin D receptor (VDR) gene polymorphisms with diabetic retinopathy (DR) susceptibility reported conflicting results. A systematic meta-analysis was undertaken to clarify this topic. Methods. A systematic search of electronic databases (PubMed, EMBASE, and CNKI) was carried out until March 31, 2016. The pooled odds ratio (OR) and 95% confidence interval (CI) were used to assess the strength of the association. Results. A total of 7 studies fulfilling the inclusion criteria were included in this meta-analysis (649 cases and 707 controls). Pooled ORs showed a significant association between FokI polymorphism and DR risk in all the four genetic models (OR = 1.612 (1.354–1.921), 1.988 (1.481–2.668), 1.889 (1.424–2.505), and 2.674 (1.493–4.790) in allelic, dominant, recessive, and additive models, resp., \( P_Z < 0.01 \)), but not for TaqI or BsmI polymorphism (\( P_Z > 0.05 \)). Similar results were found in the subgroup analysis. Sensitivity analysis indicated that the results were relatively stable and reliable. Results of Begg’s and Egger’s tests suggested a lack of publication bias. Conclusions. Our meta-analysis demonstrated that DR was significantly associated with VDR gene FokI polymorphism. However, due to the relatively small sample size in this meta-analysis, further studies with a larger sample size should be done to confirm the findings.

1. Introduction

Diabetic retinopathy (DR) is regarded as the leading cause of legal blindness in adults, characterized by increased vascular permeability, tissue ischemia, and neoangiogenesis [1, 2]. As one of the most prominent pathological microvascular complications in diabetes, the prevalence of DR in diabetes patients has been estimated at 34.6% and that of proliferative diabetic retinopathy (PDR) has been estimated at 7.0% [3], but the frequency varies in different ethnicities.

It has been established that good diabetes control helps to prevent DR; however, the mechanisms underlying the role of hyperglycemia in DR remain unclear. A subanalysis of the Diabetes Control and Complications Trial (DCCT) showed strong retinopathy transmission in families of patients with severe DR but not in those with nonsevere DR [4], supporting potential involvement of genetic factors in DR. Therefore, it is important to identify the genetic susceptibility factors for DR, which would be helpful to clarify the pathogenesis of DR.

As a secosteroid hormone, vitamin D is acquired and synthesized from the diet and ultraviolet radiation. In addition to its well-known function of maintaining normal homeostasis of calcium and phosphorus, it also has potent nonclassical properties, such as anti-inflammatory, antioxidant, antiangiogenic, and antiproliferative properties [5, 6]. It has been reported that vitamin D could inhibit vascular smooth muscle cell growth in vitro through its antiproliferative action. And vitamin D deficiency has been associated with increased prevalence of retinopathy in young T1DM [7] and T2DM [8] patients. The active form of vitamin D acts through a specific vitamin D receptor (VDR), which is widely expressed in human tissues and organs, including the retina [9]. Therefore, the gene encoding VDR is regarded as a candidate gene involved in DR and has been studied in several populations.
The human VDR gene is located on chromosome 12q13.1, with at least 5 promoter regions and 8 protein-coding exons. Several polymorphisms in the VDR gene have been suggested to be involved in the development of DR. However, the results are conflicting and inconclusive. This may be attributed to the limited sample size and inadequate statistical power, which might affect their reliability. A meta-analysis is a statistical procedure of pooling the data from individual studies, increasing effective sample size, enhancing statistical power of the analysis, and producing a single estimate of an effect [10]. Therefore, we performed a comprehensive meta-analysis to further evaluate the association of VDR gene common polymorphisms with DR susceptibility.

We focused on the polymorphisms of FokI (rs10735810), BsmI (rs1544410), ApaI (rs7975232), and TaqI (rs731236), as they had been shown to be highly polymorphic and the most studied polymorphisms.

2. Methods

2.1. Literature Search. Eligible studies were systematically searched in PubMed, EMBASE, and China National Knowledge Infrastructure (CNKI) databases up to March 31, 2016, with keywords including “diabetes OR diabetic retinopathy” and “VDR OR vitamin D receptor” and “polymorphism OR mutation OR variation OR SNP”. No language restrictions were applied. Additional studies were identified by a hand search for references of original studies and review articles about the association of VDR gene polymorphisms with DR. For detailed search strategies, please see SI (in Supplementary Material available online at http://dx.doi.org/10.1155/2016/5305282).

2.2. Inclusion and Exclusion Criteria. Studies were chosen if they met the following criteria: (1) published studies; (2) evaluated association between VDR polymorphisms and DR risk; (3) a case-control or cohort study based on unrelated individuals; (4) sufficient data for examining odds ratios (ORs) with 95% confidence intervals (CIs) of association between VDR polymorphisms and DR susceptibility was assessed through calculating the pooled odds ratios (ORs) and 95% confidence intervals (CIs) of Z test. Four genetics models were used for analyses: allelic model, dominant model, recessive model, and additive model; and the P values were corrected for multiple testing using the false discovery rate [11]. Q tests and I² statistic were used to test the heterogeneity among studies, and $P_Q > 0.10$ and $I^2 < 50\%$ were considered to be of low heterogeneity. Sensitivity analysis was conducted by sequentially excluding each study to assess the stability of the results. Publication bias was assessed by Begg’s and Egger’s tests. $P < 0.05$ was considered significant for all tests.

3. Results

3.1. Characteristics of Published Studies. A total of 360 studies were retrieved. Based on titles and/or abstracts, we excluded 36 reviews (or meta-analysis, editorials) and 309 irrelevant studies. As the result in EMBASE was the same as that in PubMed, therefore, 5 studies were retrieved. The remaining 10 studies were included for full-text view. One abstract from conference was excluded. One article was excluded owing to lack of complete data (we tried to contact the author by email and had no response until we submitted our study) [12]. One article was excluded for departure from HWE in the control group [13]. Finally, 7 eligible studies (649 cases and 707 controls) published from 2002 to 2015 were included in this meta-analysis [14–20], and the data was extracted. The study selection procedure was shown in Figure 1. Generally, the major design characteristics of all eligible studies were in accordance with the NOS tool and therefore were of relatively high quality. Reported articles about GWAS of DR were also searched.

Among the 7 studies, 6 studies focused on the association of DR risk and FokI polymorphism [14–19], 3 on TaqI polymorphism [17, 18, 20], 3 on BsmI polymorphism [14, 17, 18], and 2 on ApaI polymorphism [14, 18]. All the polymorphisms were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). A total of 4 studies included Caucasian populations [17–20], and 3 included Asian populations [14–16]. Four studies were conducted in type 2 diabetes patients [14–17, 18] and 3 in type 1 diabetes patients [17, 19, 20]. The study characteristics were displayed in Table 1, and the genotype distributions of all studies are summarized in Table 2. The distributions of the genotypes in the control populations were consistent with HWE in all of the studies ($P > 0.05$).

3.2. Association of VDR Gene FokI Polymorphism and Risk of DR. Six relevant studies with a total number of 548 cases and
Table 1: Characteristics of 7 studies included in this systematic review and meta-analysis.

| Author         | Publishing year | Population | Ethnicity | Genotyping method | Type of diabetes | Case/control  | n (case/control) | % of males (case/control) | Mean age (case/control) | Duration of diabetes (case/control) | HbA1c (case/control) |
|----------------|-----------------|------------|-----------|-------------------|------------------|---------------|------------------|--------------------------|--------------------------|-------------------------------|-------------------|
| Zhong et al.   | 2015            | Chinese    | Asian     | PCR-RFLP          | DM2              | DR/NDR        | 94/110           | 46.8/46.4                | 58.71/57.08              | 10.0/5.0                     | 9.2/8.35                     |
| Hou et al.     | 2015            | Chinese    | Asian     | PCR-RFLP          | DM2              | DR/NDR        | 162/92           | 48.4/48.9                | Not available             | Not available                | Not available              |
| Wu et al.      | 2010            | Mongolian  | Asian     | PCR-RFLP          | DM2              | DR/NC         | 62/68            | 51.6/44.1                | 53.8/51.6                | Not available                | Not available              |
| Bučan et al.   | 2009            | Croatian   | Caucasian | PCR-RFLP          | DM2              | DR/NDR        | 19/28            | Not available           | 14.6/9.7                 | 8.4/7.5                     |
| Cyganek et al. | 2006            | Polish     | Caucasian | PCR-RFLP          | DM2              | DR/NDR        | 85/182           | 42.4/46.7                | Not available             | Not available                | Not available              |
| Taverna et al. | 2005            | French     | Caucasian | PCR-RFLP          | DM1              | SDR/NSDR      | 126/128          | 46.8/53.1                | 40.7/42.9                 | 25.5/25.1                   | 9.02/7.88                   |
| Taverna et al. | 2002            | French     | Caucasian | PCR-RFLP          | DM1              | SDR/NSDR      | 101/99           | 44.6/58.6                | Not available             | 30.0/25.2                   | 8.9/8.3                     |

DM1: type 1 diabetes; DM2: type 2 diabetes.
DR: diabetic retinopathy; NDR: diabetes without retinopathy.
SDR: severe diabetic retinopathy (severe nonproliferative DR or proliferative DR); NSDR: nonsevere diabetic retinopathy (no DR or minimal nonproliferative DR).
NC: normal control.
Table 2: Genotype frequencies of VDR polymorphisms in 7 studies included in this systematic review and meta-analysis.

| Author          | Genotype frequencies | Allele frequencies | P-HWE |
|-----------------|----------------------|--------------------|-------|
|                 | Case | Control | Case     | Control |       |
| **FokI**        | FF/Ff/ff | FF/Ff/ff | F/f     | F/f     |       |
| Zhong et al.    | 11/53/30 | 35/61/14 | 75/113   | 131/89  | 0.113  |
| Hou et al.      | 10/40/71 | 12/34/46 | 60/264   | 58/126  | 0.167  |
| Wu et al.       | 6/37/19 | 21/35/12 | 49/75   | 77/59   | 0.694  |
| Bućan et al.    | 6/9/4 | 7/15/6  | 21/17   | 29/27   | 0.700  |
| Cyganek et al.  | 20/45/20 | 51/93/38 | 85/85  | 195/169 | 0.713  |
| Taverna et al.  | 38/65/23 | 57/56/15 | 141/111 | 170/86 | 0.826  |
| **BsmI**        | Bb/Bb/bb | Bb/Bb/bb | B/b   | B/b   |       |
| Zhong et al.    | 5/27/62 | 6/27/77 | 37/151 | 39/181 | 0.096  |
| Bućan et al.    | 2/10/7 | 5/16/7  | 14/24 | 26/30 | 0.431  |
| Cyganek et al.  | 10/37/38 | 21/84/77 | 57/113 | 126/238 | 0.791  |
| **TaqI**        | TT/Tt/ctt | TT/Tt/ctt | T/t | T/t |       |
| Bućan et al.    | 7/8/4 | 11/12/5 | 22/16 | 34/22 | 0.591  |
| Cyganek et al.  | 40/38/7 | 82/18/19 | 118/52 | 245/119 | 0.879  |
| Taverna et al.  | 27/58/16 | 42/44/13 | 112/90 | 128/70 | 0.783  |
| **ApaI**        | AA/Aa/aa | AA/Aa/aa | A/a   | A/a   |       |
| Zhong et al.    | 27/54/13 | 34/60/16 | 108/80 | 128/92 | 0.205  |
| Cyganek et al.  | 17/39/29 | 39/100/43 | 73/97 | 278/283 | 0.178  |

MAF: minor allele frequency.
HWE: Hardy-Weinberg equilibrium.
Table 3: Meta-analysis of VDR gene FokI polymorphism and DR susceptibility.

| Genetic model | Pooled method | $P_{Q}$ | $I^2$ (%) | OR     | 95% CI  | $P_{Z}$ (FDR) |
|---------------|---------------|---------|-----------|--------|---------|--------------|
| $f$ versus $F$| Overall       | Fixed-effect | 0.100    | 45.8   | 1.612   | 1.354-1.921  | <0.001       |
|               | Caucasian     | Fixed-effect | 0.320    | 12.3   | 1.293   | 1.013-1.650  | 0.056        |
|               | Asian         | Fixed-effect | 0.836    | 0.0    | 2.049   | 1.591-2.638  | <0.001       |
|               | DM1           | Fixed-effect | 0.206    | 37.6   | 1.418   | 1.021-1.969  | 0.057        |
|               | DM2           | Random-effect | 0.079    | 55.9   | 1.731   | 1.261-2.377  | 0.002        |

| $ff + Ff$ versus $FF$| Overall | Fixed-effect | 0.103 | 45.3 | 1.988 | 1.481-2.668 | <0.001 |
|                     | Caucasian | Fixed-effect | 0.333 | 9.2  | 1.475 | 1.061-2.142 | 0.055  |
|                     | Asian     | Fixed-effect | 0.634 | 0.0  | 3.254 | 1.995-5.308 | <0.001 |
|                     | DM1       | Fixed-effect | 0.183 | 43.7 | 1.630 | 1.012-2.626 | 0.056  |
|                     | DM2       | Random-effect | 0.091 | 53.6 | 2.396 | 1.346-4.263 | 0.005  |

| $ff$ versus $Ff + FF$| Overall | Fixed-effect | 0.317 | 15.1 | 1.889 | 1.424-2.505 | <0.001 |
|                     | Caucasian | Fixed-effect | 0.676 | 0.0  | 1.327 | 0.857-2.055 | 0.204  |
|                     | Asian     | Fixed-effect | 0.656 | 0.0  | 2.445 | 1.680-3.559 | <0.001 |
|                     | DM1       | Fixed-effect | 0.503 | 0.0  | 1.514 | 0.809-2.832 | 0.205  |
|                     | DM2       | Fixed-effect | 0.183 | 38.2 | 2.001 | 1.459-2.746 | <0.001 |

608 controls were included in FokI polymorphism analysis [14–19], 4 in type 2 diabetes patients and 2 in type 1 diabetes patients. The summary results of meta-analysis were shown in Table 3. Pooled ORs showed a significant association between FokI polymorphism and DR risk in all the four genetic models (allelic, dominant, recessive, and additive models). No significant heterogeneity was found except for additive model (Table 3).

Then, we conducted subgroup analysis stratified by population (Caucasian versus Asian). Overall, heterogeneity in all the four genetic models was not statistically significant either in Asian or in Caucasian populations, and the ORs and 95% CIs were therefore calculated in fixed-effect model. The results indicated that FokI polymorphism was significantly associated with an increased DR risk in all four genetic models (allelic, dominant, recessive, and additive models) in Asian populations; and no significant association was found in Caucasian populations (Table 3). Figure 2).

We also conducted subgroup analysis stratified by type of diabetes. A significant association between FokI polymorphism and DR risk in all four genetic models (allelic, dominant, recessive, and additive models) was found in type 2 diabetes patients; and no significant association was found in type 1 diabetes patients in all the four genetic models (Table 3).

3.3. Association of VDR Gene TaqI Polymorphism and Risk of DR. Three relevant studies with a total number of 205 cases and 309 controls were included in TaqI polymorphism analysis [17, 18, 20]. Taverna et al. first reported an association between TT genotype and low risk for severe DR in French type 1 diabetes patients [20]. However, no association was found in either study in type 1 diabetes patients by Bućan et al. [17] or study in type 2 diabetes patients by Cyganek et al. [18]. In our meta-analysis, pooled ORs and 95% CIs in four genetic models (allelic, dominant, recessive, and additive models) were 1.145 (0.879–1.492), 1.647 (0.582–4.662), 1.035 (0.600–1.785), and 1.235 (0.689–2.213), respectively. So, no significant association between TaqI polymorphism and risk of DR was suggested.

3.4. Association of VDR Gene BsmI Polymorphism and Risk of DR. Three relevant studies with a total number of 198 cases and 320 controls were included in BsmI polymorphism analysis [14, 17, 18]. All the studies were conducted in type 2 diabetes patients. Study by Wu et al. demonstrated a significant association of BsmI genotypes with cumulative prevalence of retinopathy ($P < 0.05$) [16]. However, no association was detected in studies by Zhong et al. [14] or Cyganek et al. [18]. Our meta-analysis showed no significant association between BsmI polymorphism and risk of DR, and heterogeneity was not statistically significant. Pooled
| Study ID     | OR (95% CI)       | % weight |
|--------------|-------------------|----------|
| **Asian**    |                   |          |
| Zhong et al. | 2.22 (1.49, 3.30) | 16.62    |
| Hou et al.   | 2.03 (1.33, 3.08) | 15.12    |
| Wu et al.    | 1.82 (1.07, 3.07) | 10.57    |
| **Subtotal (I² = 0.0%, P = 0.836)** | 2.05 (1.59, 2.64) | 42.30    |
| **Caucasian**|                   |          |
| Bučan et al. | 0.87 (0.38, 1.99) | 6.13     |
| Cyganek et al.| 1.15 (0.80, 1.66) | 27.32    |
| Taverna et al.| 1.56 (1.09, 2.23) | 24.25    |
| **Subtotal (I² = 12.3%, P = 0.320)** | 1.29 (1.01, 1.65) | 57.70    |
| **Overall (I² = 45.8%, P = 0.100)**  | 1.61 (1.35, 1.92) | 100.00   |

**Figure 2: Continued.**
Study ID | OR (95% CI) | % weight
--- | --- | ---
Asian  
Zhong et al. | 6.82 (2.70, 17.25) | 9.92
Hou et al. | 2.92 (1.18, 7.23) | 14.81
Wu et al. | 5.54 (1.74, 17.68) | 7.20
Subtotal (I^2 = 0.0%, P = 0.416) | 4.72 (2.70, 8.25) | 31.93
Caucasian  
Bučan et al. | 0.78 (0.15, 4.13) | 9.07
Cyganek et al. | 1.34 (0.63, 2.84) | 34.15
Taverna et al. | 2.30 (1.07, 4.96) | 24.84
Subtotal (I^2 = 0.0%, P = 0.410) | 1.62 (0.97, 2.68) | 68.07
Overall (I^2 = 54.3%, P = 0.053) | 2.61 (1.80, 3.78) | 100.00

(d) Additive model

**Figure 2:** Forest plots for meta-analysis of VDR gene FokI polymorphism and DR risk.

ORs and 95% CIs in four genetic models (allelic, dominant, recessive, and additive) were 1.031 (0.775–1.373), 1.080 (0.579–2.017), 1.025 (0.706–1.487), and 1.130 (0.587–2.175), respectively.

3.5. Association of VDR Gene ApaI Polymorphism and Risk of DR. Two relevant studies reported the association between ApaI polymorphism and risk of DR (a total of 179 cases and 292 controls). Study by Zhong et al. demonstrated that VDR gene ApaI polymorphism was not associated with DR risk in Han Chinese type 2 diabetes patients (P = 0.92) [14]. The same result was found by Cyganek et al. in Polish type 2 diabetes patients (P = 0.23) [18]. Results of meta-analysis showed no significant association between Apal polymorphism and risk of DR, and heterogeneity was not statistically significant. Pooled ORs and 95% CIs in four genetic models (allelic, dominant, recessive, and additive models) were 1.154 (0.882–1.509), 1.101 (0.710–1.707), 1.372 (0.868–2.169), and 1.308 (0.743–2.303), respectively.

3.6. Sensitivity Analysis. In the sensitivity analysis, the influence of each study on the pooled OR was examined by repeating the meta-analysis while omitting each study, one at a time. The results indicated that the overall significance of the ORs was not altered by any single study for all the four genetic models of the FokI polymorphism (Table 4). This indicated that the results of the meta-analysis about VDR gene FokI polymorphism and risk of DR were relatively stable and reliable.

3.7. Publication Bias. Potential publication bias of the meta-analysis about VDR gene FokI polymorphism and risk of DR was examined by Begg’s and Egger’s tests. Begg’s funnel plot was symmetrical in shape, and the P value of Egger’s test indicated a lack of publication bias (Table 5 and Figure 3). The results showed no evidence of obvious asymmetry for all the four genetic models.

4. Discussion

In the present study, we systematically reviewed all available published studies and performed a meta-analysis to evaluate the association of VDR gene polymorphisms with DR. Seven studies were included in this meta-analysis. Pooled ORs showed a significant association between FokI polymorphism and DR susceptibility in all the four genetic models (allelic, dominant, recessive, and additive models). Sensitivity analysis further showed that the association was stable, and Begg’s and Egger’s tests indicated a lack of publication bias. Contrary to our meta-analysis, a previous meta-analysis reported no association between FokI polymorphism and DR [21]. We believed our results were more reliable and stable based on four more included studies and larger sample size, thoughtful design, and strict criterion for the included studies.

The most investigated VDR gene polymorphism was FokI polymorphism (rs10735810), a functional T-to-C substitution at exon 2. It abolished the first translation initiation site and resulted in a peptide lacking three amino acids, which influenced the transcriptional activity of VDR [22]. The FF genotype of FokI polymorphism had been associated with higher VDR mRNA copy numbers and increased transcriptional activity of VDR [23]. So, it was presumed that potential beneficial effects of vitamin D on the retina (e.g., immunomodulatory, anti-inflammatory, antioxidant, antiangiogenic, and antiproliferative properties) were higher in patients carrying the F allele than in f-carrier patients. This association had been studied in several populations with conflicting and inconclusive results. So, we performed this meta-analysis, and our results confirmed the significant association. The results were relatively stable and reliable. In subgroup analysis, the association was limited in Asian
Table 4: Sensitivity analysis of the meta-analysis on VDR gene FokI polymorphism and DR susceptibility.

| Studies         | \(P_Q\) | \(I^2\) (%) | OR    | 95% CI         | \(P_Z\) |
|-----------------|---------|-------------|-------|----------------|---------|
| \(f\) versus \(F\) |         |             |       |                |         |
| Zhong et al.    | 0.186   | 35.3        | 1.492 | 1.227-1.814    | <0.001  |
| Hou et al.      | 0.097   | 49.2        | 1.539 | 1.269-1.866    | <0.001  |
| Wu et al.       | 0.061   | 55.6        | 1.570 | 1.173-2.101    | 0.002*  |
| Bučan et al.    | 0.137   | 42.6        | 1.661 | 1.388-1.987    | <0.001  |
| Cyganek et al.  | 0.291   | 19.5        | 1.785 | 1.461-2.180    | <0.001  |
| Taverna et al.  | 0.057   | 56.4        | 1.611 | 1.171-2.217    | 0.003*  |
| \(ff\) + \(Ff\) versus \(FF\) |         |             |       |                |         |
| Zhong et al.    | 0.177   | 36.7        | 1.770 | 1.282-2.443    | 0.001   |
| Hou et al.      | 0.061   | 55.7        | 1.974 | 1.185-3.287    | 0.009*  |
| Wu et al.       | 0.155   | 40.0        | 1.832 | 1.344-2.497    | <0.001  |
| Bučan et al.    | 0.151   | 40.5        | 2.102 | 1.552-2.846    | <0.001  |
| Cyganek et al.  | 0.172   | 37.4        | 2.301 | 1.641-3.227    | <0.001  |
| Taverna et al.  | 0.059   | 56.0        | 2.066 | 1.159-3.681    | 0.044   |
| \(ff\) versus \(Ff\) + \(FF\) |         |             |       |                |         |
| Zhong et al.    | 0.512   | 0.0         | 1.697 | 1.244-2.313    | 0.001   |
| Hou et al.      | 0.258   | 24.6        | 1.765 | 1.263-2.466    | 0.001   |
| Wu et al.       | 0.212   | 31.5        | 1.866 | 1.382-2.521    | <0.001  |
| Bučan et al.    | 0.283   | 20.7        | 1.942 | 1.455-2.592    | <0.001  |
| Cyganek et al.  | 0.573   | 0.0         | 2.152 | 1.561-2.968    | <0.001  |
| Taverna et al.  | 0.217   | 30.7        | 1.933 | 1.420-2.630    | <0.001  |
| \(ff\) versus \(FF\) |         |             |       |                |         |
| Zhong et al.    | 0.201   | 33.0        | 2.145 | 1.425-3.228    | <0.001  |
| Hou et al.      | 0.028   | 63.2        | 2.616 | 1.267-5.401    | 0.009*  |
| Wu et al.       | 0.058   | 56.1        | 2.372 | 1.263-4.456    | 0.007*  |
| Bučan et al.    | 0.066   | 54.7        | 2.999 | 1.665-5.401    | <0.001* |
| Cyganek et al.  | 0.141   | 42.1        | 3.265 | 2.122-5.023    | <0.001  |
| Taverna et al.  | 0.029   | 63.0        | 2.765 | 1.306-5.856    | 0.008*  |

* Calculated with random-effect model.

Table 5: Publication bias analysis of the meta-analysis on VDR gene FokI polymorphism and DR susceptibility.

| Genetic model       | Test         | \(t\) | 95% CI           | \(P\) |
|---------------------|--------------|-------|-----------------|------|
| \(f\) versus \(F\) | Begg’s test  | −0.49 | −8.290 to 5.814 | 1.000|
|                     | Egger’s test | −0.49 | −8.290 to 5.814 | 0.652|
| \(ff\) + \(Ff\) versus \(FF\) | Begg’s test  | 0.21  | −5.458 to 6.371 | 1.000|
|                     | Egger’s test | 0.21  | −5.458 to 6.371 | 0.841|
| \(ff\) versus \(Ff\) + \(FF\) | Begg’s test  | −0.55 | −6.146 to 4.101 | 1.000|
|                     | Egger’s test | −0.55 | −6.146 to 4.101 | 0.609|
| \(ff\) versus \(FF\) | Begg’s test  | 0.10  | −7.641 to 8.240 | 0.452|
|                     | Egger’s test | 0.10  | −7.641 to 8.240 | 0.922|

populations and in type 2 diabetes patients. The discordancy might be a result of the difference in genetic backgrounds between Asian and Caucasian populations (all the 3 studies were performed in Caucasian populations).

BSM1, Apal, and TaqI were all located at the 3’ untranslated region of the gene, which was involved in regulation of gene expression, especially through the modulation of mRNA stability [24]. It was interesting to note that significant linkage disequilibrium was found among the TaqI, Apal, and BsmI polymorphisms [25]. Although these polymorphisms had been reported to be associated with reduced steady state VDR mRNA [26], no association with risk of DR was observed in this meta-analysis. One study in Korean type 2 diabetes patients found that patients with B allele (BB or Bb) of BsmI polymorphism had significant association with lower risk of DR (severe nonproliferative DR or proliferative DR; 7.4%,
5/68) compared with patients without B allele (bb; 17.3%, 81/469; \( P = 0.035 \)) [12]. However, for deficiency of complete data, this study was not included in our meta-analysis.

Some limitations existed in the current meta-analysis that must be considered. First, the conclusion was based on a relatively small number of participants. Therefore, our results might be underpowered. Second, we performed stratification only by race and type of diabetes. The subgroup analysis by type of DR was not performed, because few studies gave data about proliferative DR and nonproliferative DR. Third, our meta-analysis was based on unadjusted estimates without being adjusted for other covariates, such as age, family history, and duration of diabetes. A large, prospective clinical study that includes additional clinical data, such as type of treatment and presence of other microvascular complications, and anthropometric parameters into account is needed to confirm the importance of VDR polymorphism in the development of DR.

**5. Conclusions**

In conclusion, our meta-analysis results indicated that there was a significant association between the VDR gene FokI polymorphism and DR susceptibility. However, due to the relatively small sample size in this meta-analysis, in order to reach a more definitive conclusion, further studies based on larger sample size and substantiation of the variations through functional studies are still needed.

**Competing Interests**

The authors declare no competing financial interests.

**Acknowledgments**

This study was supported by Henan Province Basis and Advancing Science Program (132300410362).

**References**

[1] A. H. Barnett, "Pathogenesis of diabetic microangiopathy: an overview," *The American Journal of Medicine*, vol. 90, no. 6, pp. 675–735, 1991.

[2] N. Cheung, P. Mitchell, and T. Y. Wong, "Diabetic retinopathy," *The Lancet*, vol. 376, no. 9735, pp. 124–136, 2010.

[3] J. W. Yau, S. L. Rogers, R. Kawasaki et al., "Global prevalence and major risk factors of diabetic retinopathy," *Diabetes Care*, vol. 35, no. 3, pp. 556–564, 2012.
[4] The Diabetes Control and Complications Trial Research Group, "Clustering of long-term complications in families with diabetes in the diabetes control and complications trial," *Diabetes*, vol. 46, no. 11, pp. 1829–1839, 1997.

[5] S. Basit, "Vitamin D in health and disease: a literature review," *British Journal of Biomedical Science*, vol. 70, no. 4, pp. 161–172, 2013.

[6] R. P. Heaney, "Vitamin D in health and disease," *Clinical Journal of the American Society of Nephrology*, vol. 3, no. 5, pp. 1535–1541, 2008.

[7] H. Kaur, K. C. Donaghue, A. K. Chan et al., "Vitamin D deficiency is associated with retinopathy in children and adolescents with type 1 diabetes," *Diabetes Care*, vol. 34, no. 6, pp. 1400–1402, 2011.

[8] P. A. Patrick, P. F. Visintainer, Q. Shi, I. A. Weiss, and D. A. Brand, "Vitamin D and retinopathy in adults with diabetes mellitus," *Archives of Ophthalmology*, vol. 130, no. 6, pp. 756–760, 2012.

[9] J. A. Johnson, J. P. Grande, P. C. Roche, R. J. Campbell, and R. Kumar, "Immu-no-localization of the calcitriol receptor, calbindin-d28k and the plasma membrane calcium pump in the human eye," *Current Eye Research*, vol. 14, no. 2, pp. 101–108, 1995.

[10] Y. H. Lee, "Meta-analysis of genetic association studies," *Annals of Laboratory Medicine*, vol. 35, no. 3, pp. 283–287, 2015.

[11] Y. Benajminini, D. Drai, G. Elmer, N. Kalkafi, and I. Golani, "Controlling the false discovery rate in behavior genetics research," *Behavioural Brain Research*, vol. 125, no. 1-2, pp. 279–284, 2001.

[12] Y. J. Hong, E. S. Kang, M. J. Ji et al., "Association between Bsm1 polymorphism in vitamin D receptor gene and diabetic retinopathy of Type 2 diabetes in Korean population," *Endocrinology and Metabolism*, vol. 30, no. 4, pp. 469–474, 2015.

[13] J. H. Sun, Y. Y. Chen, C. M. Liu et al., "The relationship between vitamin D receptor gene TaqI polymorphism and diabetic retinopathy," *Chinese Journal of Ocular Fundus Diseases*, vol. 22, no. 2, pp. 94–96, 2006.

[14] X. Zhong, Y. Du, Y. Lei, N. Liu, Y. Guo, and T. Pan, "Effects of vitamin D receptor gene polymorphism and clinical characteristics on risk of diabetic retinopathy in Han Chinese type 2 diabetes patients," *Gene*, vol. 566, no. 2, pp. 212–216, 2015.

[15] L. J. Hou, D. H. Huang, and J. J. Han, "Relationship between Vitamin D receptor gene FokI polymorphism and diabetic retinopathy in China," *Journal of Taishan Medical College*, vol. 36, no. 5, pp. 490–493, 2015.

[16] Y. N. Wu, Y. P. Zhang, and A. P. Wang, "Association between DNA polymorphism of human Vitamin D receptor (VDR) gene and Type 2 diabetic retinopathy in mongolian people," *Inner Mongolia Medical Journal*, vol. 42, no. 3, pp. 271–274, 2010.

[17] K. Bučan, M. Ivanišević, T. Zemunik et al., "Retinopathy and nephropathy in type 1 diabetic patients—association with polymorphisms of vitamin D-receptor, TNF, Neuro-D and IL-1 receptor 1 genes," *Collegium Antropologicum*, vol. 33, supplement 2, pp. 99–105, 2009.

[18] K. Cyganek, B. Mirkiewicz-Sieradzka, M. T. Malecki et al., "Clinical risk factors and the role of VDR gene polymorphisms in diabetic retinopathy in Polish type 2 diabetes patients," *Acta Diabetologica*, vol. 43, no. 4, pp. 114–119, 2006.

[19] M. J. Taverna, J.-L. Selam, and G. Slama, "Association between a protein polymorphism in the start codon of the vitamin D receptor gene and severe diabetic retinopathy in C-peptide-negative type 1 diabetes," *Journal of Clinical Endocrinology and Metabolism*, vol. 90, no. 8, pp. 4803–4808, 2005.